Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

Can Biogen Save Even More Kids With This New Drug?

Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.

Investors Business Daily

Stocks With Rising Relative Strength: Novartis ADR

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?

Investors Business Daily

Americans would suffer most if Trump imposes pharma tariffs, sector warns

Industry says levies would hit supply chains, making medicines potentially unaffordable for some US patients

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point

Novartis stock made a break for a buy point Tuesday after the drugmaker beat first-quarter expectations and raised its full-year outlook.

Investors Business Daily

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot

The Guardian - UK

Novartis posts better-than-expected sales driven by medicine demand

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core operating income set to grow by low double-digits.

Euronews

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Pill that slashes risk of breast cancer recurring to be available on NHS

Ribociclib (known by the brand name Kisqali) targets specific proteins that contribute to cancer cell growth

The Independent UK

EU holds firm on pharma reform proposal despite industry pressure

The European Commission has no plans to withdraw or revise its proposed overhaul of EU pharmaceutical rules, despite mounting pressure from the pharmaceutical industry concerned about potential tariffs and the sector’s competitiveness.

Euronews

Roche Says Will Invest $50 Bn In US, As Tariff War Uncertainty Swells

Trump's administration is blowing hot and cold on pharmaceutical products, which initially benefited from exemptions in the round of tariffs announced on April 2.

Latin Times

Swiss drugmaker Roche leans into Trump tariff formula with $50bn promise to invest in U.S.

Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.

Fortune

Novartis ADR Scores Relative Strength Rating Upgrade; Hits Key Benchmark

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance.

Investors Business Daily

Novartis Plans $23 Billion US Buildout as Pharma Faces Pressure From Trump

Novartis plans a $23 billion U.S. expansion to boost drug production and counter potential import tariffs.

Latin Times

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Investors Business Daily

Stocks Showing Improving Market Leadership: Novartis ADR Earns 83 RS Rating

Novartis ADR sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Stocks To Watch: Novartis ADR Sees RS Rating Jump To 83

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance.

Investors Business Daily

Novartis ADR Receives Composite Rating Upgrade

On Wednesday, Novartis ADR got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Behind $2 million per dose gene therapy

How did a drug rooted in government seed money and spurred by grassroots fundraising end up with such a price tag?

The Independent UK

Aliens, sloths and silliness: Super Bowl ads offer laughs, celebs and surprises to win over viewers

Eugene Levy’s trademark eyebrows fly off for Little Caesars

Investors Business Daily

Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition

Novartis stock closed flat Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.

MarketBeat

AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Benzinga

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Investors Business Daily

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Benzinga

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

the European Parliament

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.